Encephalopathy - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Encephalopathy - Pipeline Review, H1 2016

Encephalopathy - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Encephalopathy - Pipeline Review, H1 2016
Published Jun 08, 2016
72 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Encephalopathy - Pipeline Review, H1 2016, provides an overview of the Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Encephalopathy
- The report reviews pipeline therapeutics for Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Encephalopathy therapeutics and enlists all their major and minor projects
- The report assesses Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Encephalopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Encephalopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Encephalopathy pipeline depth and focus of Indication therapeutics
- Develop an

  
Source:
Document ID
GMDHC8204IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Encephalopathy Overview81
Therapeutics Development92
  Pipeline Products for Encephalopathy Overview91
  Pipeline Products for Encephalopathy Comparative Analysis101
Encephalopathy Therapeutics under Development by Companies111
Encephalopathy Therapeutics under Investigation by Universities/Institutes121
Encephalopathy Pipeline Products Glance132
  Clinical Stage Products131
  Early Stage Products141
Encephalopathy Products under Development by Companies151
Encephalopathy Products under Investigation by Universities/Institutes161
Encephalopathy Companies Involved in Therapeutics Development1712
  Amarantus Bioscience Holdings, Inc.171
  Celgene Corporation181
  Chiesi Farmaceutici SpA191
  Fera Pharmaceuticals, LLC201
  GW Pharmaceuticals Plc211
  JS Genetics Inc.221
  KannaLife Sciences, Inc.231
  ProThera Biologics, LLC.241
  SciFluor Life Sciences, LLC251
  Turing Pharmaceuticals AG261
  Versantis271
  Zambon Company S.p.A.281
Encephalopathy Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3820
  Alda-1 - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  AMRS-001 - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress393
  cannabidiol - Drug Profile421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  diazoxide - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress432
  EUC-001 - Drug Profile451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  GWP-42003 - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress462
  melatonin - Drug Profile481
    Product Description481
    Mechanism of Action481
    R&D Progress481
  phenobarbitol sodium - Drug Profile491
    Product Description491
    Mechanism of Action491
    R&D Progress491
  Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  SF-0034 - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress511
  Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy - Drug Profile521
    Product Description521
    Mechanism of Action521
    R&D Progress521
  TRP-005 - Drug Profile531
    Product Description531
    Mechanism of Action531
    R&D Progress531
  TRP-601 - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  TUR-004 - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  VS-01 - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  ZP-053 - Drug Profile571
    Product Description571
    Mechanism of Action571
    R&D Progress571
Encephalopathy Recent Pipeline Updates5810
Encephalopathy Product Development Milestones683
  Featured News &Press Releases681
    Feb 29, 2016: Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE681
    Nov 16, 2015: Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies681
    Oct 23, 2015: Turing Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application and Fast Track Designation for TUR-004681
    Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy691
    Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy701
Appendix712
  Methodology711
  Coverage711
  Secondary Research711
  Primary Research711
  Expert Panel Validation711
  Contact Us711
  Disclaimer721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Encephalopathy - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Encephalopathy-Pipeline-Review-H1-2016-2088-15925>
  
APA:
Global Markets Direct - Market Research. (2016). Encephalopathy - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Encephalopathy-Pipeline-Review-H1-2016-2088-15925>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.